← Back to Search

P2Y12 inhibitor

cangrelor for Acute Coronary Syndrome (CHAMPION Trial)

Phase 3
Waitlist Available
Research Sponsored by The Medicines Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours after randomization
Awards & highlights

Summary

The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).

Eligible Conditions
  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention
  • Atherosclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours after randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours after randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)
Secondary outcome measures
Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild
Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: cangrelorExperimental Treatment2 Interventions
Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours. Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered.
Group II: clopidogrelActive Control1 Intervention
Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion. During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cangrelor
FDA approved
Cangrelor
FDA approved

Find a Location

Who is running the clinical trial?

The Medicines CompanyLead Sponsor
71 Previous Clinical Trials
66,510 Total Patients Enrolled
8 Trials studying Acute Coronary Syndrome
31,525 Patients Enrolled for Acute Coronary Syndrome
~743 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top